{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:23:19Z","timestamp":1784848999160,"version":"3.55.0"},"reference-count":30,"publisher":"IMR Press","issue":"10","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: Papillary thyroid cancer (PTC) is an endocrine malignancy whose incidence has increased rapidly worldwide. MAP17 (PDZKIP1) is a small protein related to tumor progression. The aim of this study was to investigate the role of MAP17 in PTC and the underlying molecular mechanism. Methods: Bioinformatics, Western blotting and immunohistochemistry were used to analyze the expression of MAP17 in PTC. The gene transcription was measured by qPCR. Cell viability was determined by CCK8 assay. Cell growth was measured by clonal formation assay. Cell apoptosis was measured by TUNEL. Wound healing assay and transwell assay were used to measure the mobility of cells. The expression of E-cadherin and N-cadherin was determined by immunofluorescence. The effect of MAP17 on tumor growth was determined in animal experiments. Results: The results showed that MAP17 was up-regulated in PTC, which significantly promoted the growth and motility of PTC cells, but inhibited cell apoptosis. Besides, overexpression of MAP17 accelerated cycloheximide (CHX, a protein synthesis inhibitor)-induced p53 degradation, while low expression of MAP17 slowed down CHX-induced p53 degradation, suggesting that MAP17 can regulate p53 stability. Notably, NUMB exhibited an opposite effect on P53 stability. Interestingly, p53 overexpression reversed the effects of MAP17 overexpression on cell viability, motility, and apoptosis, indicating that p53 was involved in the progression of PTC. In vivo studies have shown that tumor growth was positively correlated with MAP17 expression and negatively correlated with p53 expression. Conclusion: Our findings revealed that MAP17 exhibited carcinogenic effects through interacting with NUMB to reduce the stability of p53, demonstrating that MAP17 may serve as a potential prognostic biomarker for PTC treatment.<\/jats:p>","DOI":"10.52586\/4987","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T07:57:21Z","timestamp":1635494241000},"source":"Crossref","is-referenced-by-count":7,"title":["80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53"],"prefix":"10.31083","volume":"26","author":[{"given":"Kun","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Head and Neck Surgery, Center of Otolaryngology-Head and Neck Surgery, Zhejiang Provincial People\u2019s Hospital, People\u2019s Hospital of Hangzhou Medical College, Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiang","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Radiology, The 903 Hospital of the joint logistics support force of the Chinese people\u2019s Liberation Army, 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Chen","sequence":"first","affiliation":[{"name":"Laboratory Animal Center, Zhejiang University, 310058 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xin","sequence":"first","affiliation":[{"name":"Department of Head and Neck Surgery, Center of Otolaryngology-Head and Neck Surgery, Zhejiang Provincial People\u2019s Hospital, People\u2019s Hospital of Hangzhou Medical College, Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Head and Neck Surgery, Center of Otolaryngology-Head and Neck Surgery, Zhejiang Provincial People\u2019s Hospital, People\u2019s Hospital of Hangzhou Medical College, Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Breasts Surgery, Center of Otolaryngology-Head and Neck Surgery, Zhejiang Provincial People\u2019s Hospital, People\u2019s Hospital of Hangzhou Medical College, Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, 310014 Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kwon H, Cheon Y, Shin S, Sung E, Lee J, Kim IJ, et al. Risk factors of suprasternal lymph node metastasis in papillary thyroid carcinoma with clinical lateral cervical lymph node metastasis. Gland Surgery. 2021; 10: 512\u2013520.","DOI":"10.21037\/gs-20-368"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ho AS, Davies L, Nixon IJ, Palmer FL, Wang LY, Patel SG, et al. Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. Cancer. 2015; 121: 1793\u20131799.","DOI":"10.1002\/cncr.29289"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A. Prognostic Factors for Recurrence of Papillary Thyroid Carcinoma in the Lymph Nodes, Lung, and Bone: Analysis of 5,768 Patients with Average 10-year Follow-up. World Journal of Surgery. 2012; 36: 1274\u20131278.","DOI":"10.1007\/s00268-012-1423-5"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Moo T, McGill J, Allendorf J, Lee J, Fahey T, Zarnegar R. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World Journal of Surgery. 2010; 34: 1187\u20131191.","DOI":"10.1007\/s00268-010-0418-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer. 2012; 118: 3426\u20133432.","DOI":"10.1002\/cncr.26587"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Guijarro MV, Link W, Rosado A, Leal JFM, Carnero A. MAP17 inhibits Myc-induced apoptosis through PI3K\/AKT pathway activation. Carcinogenesis. 2007; 28: 2443\u20132450.","DOI":"10.1093\/carcin\/bgm154"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Pribanic S, Gisler SM, Bacic D, Madjdpour C, Hernando N, Sorribas V, et al. Interactions of MAP17 with the NaPi-IIa\/PDZK1 protein complex in renal proximal tubular cells. American Journal of Physiology. Renal Physiology. 2003; 285: F784\u2013F791.","DOI":"10.1152\/ajprenal.00109.2003"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Carnero A. MAP17 and the double-edged sword of ROS. Biochimica Et Biophysica Acta. 2012; 1826: 44\u201352.","DOI":"10.1016\/j.bbcan.2012.03.004"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Perez M, Praena-Fernandez JM, Felipe-Abrio B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, et al. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. PLoS ONE. 2013; 8: e56169.","DOI":"10.1371\/journal.pone.0056169"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Guijarro MV, Vergel M, Marin JJ, Mu\u00f1oz-Galv\u00e1n S, Ferrer I, Ramon y Cajal S, et al. P38\u03b1 limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene. 2012; 31: 4447\u20134459.","DOI":"10.1038\/onc.2011.619"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Guijarro MV, Leal JFM, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, et al. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis. 2007; 28: 1646\u20131652.","DOI":"10.1093\/carcin\/bgm083"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ragazzi M, Torricelli F, Donati B, Ciarrocchi A, de Biase D, Tallini G, et al. Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature. Virchows Archiv. 2020; 478: 265\u2013281.","DOI":"10.1007\/s00428-020-02891-9"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Dhami GK, Liu H, Galka M, Voss C, Wei R, Muranko K, et al. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis. Molecular Cell. 2013; 50: 565\u2013576.","DOI":"10.1016\/j.molcel.2013.04.028"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Siddique HR, Feldman DE, Chen C, Punj V, Tokumitsu H, Machida K. NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer. Hepatology. 2015; 62: 1466\u20131479.","DOI":"10.1002\/hep.27987"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Liu L, Lanner F, Lendahl U, Das D. Numblike and Numb differentially affect p53 and Sonic Hedgehog signaling. Biochemical and Biophysical Research Communications. 2011; 413: 426\u2013431.","DOI":"10.1016\/j.bbrc.2011.08.108"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Garcia-Heredia JM, Lucena-Cacace A, Verdugo-Sivianes EM, P\u00e9rez M, Carnero A. The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. Clinical Cancer Research. 2017; 23: 3871\u20133883.","DOI":"10.1158\/1078-0432.CCR-16-2358"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19: 649\u2013658.","DOI":"10.1016\/j.neo.2017.05.002"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research. 2017; 45: W98\u2013W102.","DOI":"10.1093\/nar\/gkx247"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Park JL, Kim SK. MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer. Cancers. 2021; 13: 632.","DOI":"10.3390\/cancers13040632"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Wang W, Wen Q, Luo J, Chu S, Chen L, Xu L, et al. Suppression of \u03b2-catenin Nuclear Translocation by CGP57380 Decelerates Poor Progression and Potentiates Radiation-Induced Apoptosis in Nasopharyngeal Carcinoma. Theranostics. 2017; 7: 2134\u20132149.","DOI":"10.7150\/thno.17665"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kim WB, Jeon MJ, Kim WG, Kim TY, Shong YK. Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer. Endocrinology and Metabolism. 2020; 35: 14\u201325.","DOI":"10.3803\/EnM.2020.35.1.14"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. Journal of the American Medical Association. 2017; 317: 1338\u20131348.","DOI":"10.1001\/jama.2017.2719"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"I\u00f1iguez-Ariza NM, Brito JP. Management of Low-Risk Papillary Thyroid Cancer. Endocrinology and Metabolism. 2018; 33: 185\u2013194.","DOI":"10.3803\/EnM.2018.33.2.185"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Li Z, Lin W, Zheng J, Hong W, Zou J, Zhang T, et al. Identification of immune-related lncRNAs to improve the prognosis prediction for patients with papillary thyroid cancer. Bioscience Reports. 2021; 41: BSR20204086.","DOI":"10.1042\/BSR20204086"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ban EJ, Kim D, Kim JK, Kang S, Lee J, Jeong JJ, et al. Lactate Dehydrogenase a as a Potential New Biomarker for Thyroid Cancer. Endocrinology and Metabolism. 2021; 36: 96\u2013105.","DOI":"10.3803\/EnM.2020.819"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Liang Q, Zhang H. MAP17 contributes to non-small cell lung cancer progression via suppressing miR-27a-3p expression and p38 signaling pathway. Cancer Biology & Therapy. 2021; 22: 19\u201329.","DOI":"10.1080\/15384047.2020.1836948"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Tampaki EC, Tampakis A, Nonni A, von Fl\u00fce M, Patsouris E, Kontzoglou K, et al. Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence. Molecular Diagnosis & Therapy. 2019; 23: 635\u2013644.","DOI":"10.1007\/s40291-019-00411-3"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Ferrer I, Quintanal-Villalonga \u00c1, Molina-Pinelo S, Garcia-Heredia JM, Perez M, Su\u00e1rez R, et al. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. Journal of Experimental & Clinical Cancer Research. 2018; 37: 195.","DOI":"10.1186\/s13046-018-0871-7"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Rodero S, Fern\u00e1ndez AF, Fern\u00e1ndez-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. The Journal of Clinical Endocrinology and Metabolism. 2013; 98: 2811\u20132821.","DOI":"10.1210\/jc.2012-3566"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Borggrefe T, Oswald F. The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cellular and Molecular Life Sciences. 2009; 66: 1631\u20131646.","DOI":"10.1007\/s00018-009-8668-7"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/26\/10\/10.52586\/4987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:21:04Z","timestamp":1732706464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/26\/10\/10.52586\/4987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"alternative-id":["s2768-6701(21)00061-7"],"URL":"https:\/\/doi.org\/10.52586\/4987","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]},"article-number":"777"}}